Psychedelic Research in
Anguilla
Anguilla has no linked psychedelic trials, active trials, stakeholders or events in Blossom's database, and the public record shows no established medical psychedelic programme. The island's health system is small and largely service-oriented, with policy emphasis on quality management and general health services rather than controlled-substance research.
Key Insights
A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Anguilla.
- 1
The legal environment is clearly prohibitive for controlled psychedelics, with offences and penalties set out in local drug law rather than any special therapeutic access scheme.
- 2
The available health-policy material points to quality, surveillance and service governance, not to a research-intensive or specialist psychedelic ecosystem.
- 3
I found no public sign of local clinical-trial activity in psychedelics, which is consistent with Blossom's zero linked-trial count.
- 4
The presence of narrow medical or scientific exemptions means lawful handling may exist in principle, but the sources do not identify any operational psychedelic programme or licensed provider.
- 5
Ketamine's WHO essential-medicine status supports its general medical legitimacy, but it should not be read as evidence of esketamine approval, reimbursement, or psychedelic-assisted therapy availability in Anguilla.
Research Snapshot
Blossom currently keeps Anguilla as a country index, but no psychedelic clinical trials, stakeholders or events are linked to this country in the database yet.
Missing linked records are database coverage signals, not proof that no local policy discussion, care or informal activity exists.
- Active trials
- 0
- Total trials
- 0
- Stakeholders
- 0
- Events
- 0
None marked active
No linked trials
No linked stakeholders
No linked events
Top Compounds
No headline compound signal is available from linked country trials yet.
Top Study Topics
No study-topic signal is available from linked country trials yet.
Medical Access Snapshot
Anguilla (a British Overseas Territory) maintains strict controls on most classical psychedelics under its criminal/drug-control framework and through regional enforcement practice; there is no publicly documented, reimbursed medical psychedelic program on the island. Ketamine is used in routine clinical practice internationally as an anaesthetic (and is on the WHO essential medicines list), but there is no evidence of an esketamine (Spravato) approval, public reimbursement program, or established psychedelic-assisted therapy roll-out in Anguilla...
Regulatory Status
Anguilla's Drugs (Prevention of Misuse) Act and Controlled Drugs Regulations create a controlled-drug framework that criminalises production, supply and possession, while allowing narrow medical or scientific exemptions and hospital/prescription controls. Publicly available sources do not show an Anguilla-specific regulatory pathway for psilocybin, MDMA, LSD, DMT or esketamine, and I found no evidence of a public medical psychedelic programme; ketamine is listed by WHO as an essential medicine, but that does not by itself indicate local psychedelic-treatment access. Given the limited public detail and reliance on older health-system profiling, some access conclusions remain cautious rather than definitive.
Country Details
- Region
- North America
- Last updated
- 4 May 2026
Country Report
Medical Only (Private)Medical Access and Reimbursement
Anguilla (a British Overseas Territory) maintains strict controls on most classical psychedelics under its criminal/drug-control framework and through regional enforcement practice; there is no publicly documented, reimbursed medical psychedelic program on the island. Ketamine is used in routine...
Open access guide →